V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330007322 | 330012400 | 1.65 | 52.2 | null | 2015-06-15 | 2015-07-04 | CISPLATIN + FLUOROURACIL | N | null | 330008964 | CISPLATIN + FLUOROURACIL |
| 330007323 | 330004121 | 1.68 | 68.1 | Not known (9) | 2017-06-23 | 2017-06-26 | PAM x 2 post-surgery (cycles 3&4) | 2 | Y | 330008977 | MAP |
| 330007324 | 330004125 | null | 19.9 | Palliative (P) | 2016-11-24 | 2016-12-16 | Rituximab (Maintenance) | N | N | 330008977 | RITUXIMAB |
| 330007325 | 330004126 | null | null | Palliative (P) | 2014-01-09 | 2014-01-09 | Cetuximab 14 day | N | N | 330008992 | CETUXIMAB |
| 330007326 | 330004127 | 1.76 | 85 | Curative (C) | 2014-01-12 | 2014-02-10 | Etoposide + Ifosfamide (5 days) | N | N | 330009018 | ETOPOSIDE + IFOSFAMIDE |
| 330007327 | 330004128 | 0 | 97.9 | Palliative (P) | 2015-08-23 | 2015-09-09 | DOCETAXEL + GEMCITABINE | 02 | N | 330009018 | DOCETAXEL + GEMCITABINE |
| 330007328 | 330004128 | 1.69 | 61 | Radical (R) | null | 2015-10-09 | Cisplatin +Fluorouracil (3 wk) | N | N | 330009018 | CISPLATIN + FLUOROURACIL |
| 330007329 | 330004128 | 1.71 | 66 | Palliative (P) | 2014-11-09 | 2014-11-11 | Docetaxel+Gemcitabine (no prior RT) | 02 | N | 330009018 | DOCETAXEL + GEMCITABINE |
| 330007330 | 330012403 | 1.79 | 92.3 | null | 2017-06-12 | 2017-06-15 | Cisplatin +Fluorouracil (3 wk) | 02 | N | 330009032 | CISPLATIN + FLUOROURACIL |
| 330007331 | 330013030 | 1.62 | 60.7 | Palliative (P) | 2016-01-02 | 2016-01-16 | CETUXIMAB | N | N | 330009044 | CETUXIMAB |
| 330007332 | 330004134 | 0 | 54.8 | Adjuvant (A) | 2015-01-02 | 2015-01-06 | PAM x 2 pre-surgery (cycles 1&2) | 2 | Y | 330009044 | MAP |
| 330007333 | 330004134 | 1.62 | 75.1 | Neo-adjuvant (N) | 2014-06-21 | 2014-06-26 | OST Euramos 1 Closed Trial - M | N | N | 330009044 | METHOTREXATE HIGH DOSE |
| 330007336 | 330004138 | 1.8 | 61 | Curative (C) | 2013-12-18 | 2014-07-28 | CISPLATIN + FLUOROURACIL | N | N | 330009071 | CISPLATIN + FLUOROURACIL |
| 330007337 | 330008262 | 1.8 | 110 | Curative (C) | 2015-04-25 | 2015-05-19 | Carboplatin AUC 2 - 5 | 2 | N | 330009075 | CARBOPLATIN |
| 330007338 | 330008262 | 1.68 | 85 | Disease modification (D) | null | 2017-07-27 | Rituximab | N | N | 330009075 | RITUXIMAB |
| 330007339 | 330008262 | 1.81 | 65.5 | Disease modification (D) | 2015-01-31 | 2015-01-31 | OST Euramos 1 Closed Trial - M | N | N | 330009075 | METHOTREXATE HIGH DOSE |
| 330007344 | 330004145 | 1.62 | 0 | null | 2015-02-19 | 2015-02-19 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330009102 | MAP |
| 330007345 | 330004146 | 1.9 | 65.4 | Palliative (P) | 2018-03-18 | 2018-03-21 | Rituximab (Maintenance) | 2 | N | 330009102 | RITUXIMAB |
| 330007346 | 330004146 | 1.78 | 89.1 | null | 2015-12-28 | 2016-01-25 | MAP | N | N | 330009102 | MAP |
| 330007347 | 330004147 | 1.59 | 68 | Curative (C) | 2016-10-09 | 2016-10-09 | CISPLATIN + FLUOROURACIL | 2 | null | 330009110 | CISPLATIN + FLUOROURACIL |
| 330007348 | 330004148 | 1.62 | 91.85 | Curative (C) | 2017-05-05 | 2017-06-16 | Carboplatin AUC 2 - 5 | N | N | 330009115 | CARBOPLATIN |
| 330007349 | 330004149 | null | null | Radical (R) | 2014-12-14 | 2014-12-25 | Cisplatin +Fluorouracil (3 wk) | null | null | 330009119 | CISPLATIN + FLUOROURACIL |
| 330007350 | 330004149 | null | 75.3 | Palliative (P) | 2017-08-24 | 2017-09-18 | Cisplatin +Fluorouracil (3 wk) | N | N | 330009119 | CISPLATIN + FLUOROURACIL |
| 330007351 | 330004149 | 0 | 112 | Palliative (P) | 2015-08-18 | 2015-08-18 | DOCETAXEL + GEMCITABINE | N | N | 330009119 | DOCETAXEL + GEMCITABINE |
| 330007352 | 330004150 | 1.64 | null | Curative (C) | 2016-03-18 | 2016-03-31 | Rituximab (Maintenance) | N | null | 330009138 | RITUXIMAB |
| 330007353 | 330008270 | 0 | 99 | Neo-adjuvant (N) | 2013-04-25 | 2013-05-10 | PAM x 2 post-surgery (cycles 3&4) | 1 | N | 330009140 | MAP |
| 330007354 | 330004152 | 1.76 | 99.3 | Curative (C) | 2015-08-14 | 2015-09-09 | Cetuximab 7 day (>Cycle 2) | N | Y | 330009140 | CETUXIMAB |
| 330007355 | 330004152 | 1.46 | 52 | Palliative (P) | 2015-12-25 | 2015-12-31 | DOCETAXEL + GEMCITABINE | 2 | N | 330009140 | DOCETAXEL + GEMCITABINE |
| 330007356 | 330004152 | 0 | 58.2 | Palliative (P) | 2017-12-10 | 2018-01-04 | Etoposide + Ifosfamide (3 days) | 2 | Y | 330009140 | ETOPOSIDE + IFOSFAMIDE |
| 330007357 | 330004154 | 1.68 | 58 | Neo-adjuvant (N) | 2016-12-01 | 2016-12-02 | DOCETAXEL + GEMCITABINE | 2 | N | 330009166 | DOCETAXEL + GEMCITABINE |
| 330007358 | 330004156 | 1.73 | 88 | Curative (C) | 2015-08-17 | 2015-08-17 | PAM x 2 pre-surgery (cycles 1&2) | null | null | 330009169 | MAP |
| 330007359 | 330004158 | 1.8 | null | Curative (C) | 2015-07-19 | 2015-07-26 | CISPLATIN + FLUOROURACIL | N | N | 330009183 | CISPLATIN + FLUOROURACIL |
| 330007360 | 330004158 | 1.73 | 63.65 | Palliative (P) | 2016-06-26 | 2016-06-28 | Cetuximab 14 day | null | null | 330009183 | CETUXIMAB |
| 330007361 | 330008276 | 1.69 | null | Curative (C) | 2013-05-21 | 2013-06-01 | Etoposide + Ifosfamide (5 days) | Y | N | 330009194 | ETOPOSIDE + IFOSFAMIDE |
| 330007362 | 330004164 | 1.69 | 48.6 | Curative (C) | 2016-04-17 | 2016-04-17 | Carboplatin AUC 2 - 5 | 02 | Y | 330009204 | CARBOPLATIN |
| 330007363 | 330004164 | 1.78 | 77.7 | Palliative (P) | 2015-10-25 | 2015-12-06 | CISPLATIN + FLUOROURACIL | 02 | N | 330009204 | CISPLATIN + FLUOROURACIL |
| 330007364 | 330004165 | 1.67 | 81.7 | Curative (C) | 2012-12-11 | 2013-05-09 | Cetuximab 7 day (>Cycle 2) | N | N | 330009223 | CETUXIMAB |
| 330007365 | 330004167 | 1.55 | 56.5 | Curative (C) | 2015-05-31 | 2015-06-08 | Rituximab | N | Y | 330009226 | RITUXIMAB |
| 330007366 | 330004168 | 1.83 | 71.8 | Palliative (P) | 2017-07-18 | 2017-12-17 | Etoposide + Ifosfamide (3 days) | N | N | 330009243 | ETOPOSIDE + IFOSFAMIDE |
| 330007367 | 330004169 | 1.71 | 78 | Palliative (P) | 2016-06-17 | 2016-06-28 | Etoposide + Ifosfamide (3 days) | N | N | 330009250 | ETOPOSIDE + IFOSFAMIDE |
| 330007368 | 330004169 | 1.81 | 78.6 | Curative (C) | 2013-03-01 | 2013-03-01 | CISPLATIN + FLUOROURACIL | 02 | N | 330009250 | CISPLATIN + FLUOROURACIL |
| 330007369 | 330004174 | 1.62 | 81 | Curative (C) | 2016-04-14 | 2016-05-08 | OST Euramos 1 Closed Trial - M | Y | N | 330009255 | METHOTREXATE HIGH DOSE |
| 330007370 | 330004175 | 1.58 | 58 | Curative (C) | 2015-05-16 | 2015-06-05 | Rituximab | N | Y | 330009255 | RITUXIMAB |
| 330007371 | 330011718 | 1.64 | 83.6 | Curative (C) | 2015-08-22 | 2015-09-17 | Rituximab | N | N | 330009266 | RITUXIMAB |
| 330007372 | 330004176 | 1.8 | 76.25 | Palliative (P) | 2013-05-05 | 2013-11-24 | Rituximab | N | N | 330009267 | RITUXIMAB |
| 330007373 | 330004177 | null | null | Palliative (P) | 2014-02-15 | 2014-03-26 | Rituximab | N | N | 330009271 | RITUXIMAB |
| 330007374 | 330004177 | 1.81 | 52.2 | Palliative (P) | 2014-02-16 | 2014-02-18 | Cetuximab 7 day (>Cycle 2) | null | null | 330009271 | CETUXIMAB |
| 330007375 | 330004177 | null | 58 | Curative (C) | 2016-08-31 | 2016-08-31 | Rituximab | N | N | 330009271 | RITUXIMAB |
| 330007376 | 330004181 | 1.78 | 90.8 | Curative (C) | 2014-08-11 | 2014-08-20 | Carboplatin AUC 2 - 5 | N | N | 330009284 | CARBOPLATIN |
| 330007377 | 330004182 | 1.7 | 52 | Curative (C) | 2014-11-01 | 2014-11-02 | Rituximab (Maintenance) | N | N | 330009285 | RITUXIMAB |